Neurocrine Biosciences, Inc.

-3.12 (-4.13%)
Products, Regulatory

Neurocrine Biosciences Announces Positive Phase 3 Data For Kinect-Hd Study Evaluating Valbenazine For Chorea Associated With Huntington Disease

Published: 12/07/2021 21:47 GMT
Neurocrine Biosciences, Inc. (NBIX) - Neurocrine Biosciences Announces Positive Phase 3 Data for Kinect-hd Study Evaluating Valbenazine for Chorea Associated With Huntington Disease.
Neurocrine Biosciences Inc - Highly Statistically Significant Reduction in Chorea Movements.
Neurocrine Biosciences Inc - Placebo-adjusted Mean Reduction in Tmc Score of 3.2 Units in Valbenazine-treated Patients.
Neurocrine Biosciences Inc - Plans to Submit Supplemental New Drug Application to U.S. Food and Drug Administration in 2022.
Neurocrine Biosciences Inc - Study Met Primary Endpoint of Reduction in Severity of Chorea.
Neurocrine Biosciences Inc - Treatment Emergent Adverse Events Observed in This Trial Were Consistent With Known Safety Profile of Valbenazine.
Neurocrine Biosciences Inc - No Suicidal Behavior Or Worsening of Suicidal Ideation Was Observed in Valbenazine-treated Subjects in This Study.